LLY - Eli Lilly and Company

NYSE - NYSE Delayed Price. Currency in USD
122.13
-0.35 (-0.29%)
At close: 4:03PM EST

121.75 -0.38 (-0.31%)
Pre-Market: 8:08AM EST

Stock chart is not supported by your current browser
Previous Close122.48
Open121.31
Bid120.76 x 3200
Ask121.75 x 1400
Day's Range121.30 - 123.33
52 Week Range74.51 - 123.33
Volume17,861,446
Avg. Volume5,885,385
Market Cap126.456B
Beta (3Y Monthly)0.48
PE Ratio (TTM)39.06
EPS (TTM)3.13
Earnings DateApr 30, 2019
Forward Dividend & Yield2.58 (2.14%)
Ex-Dividend Date2019-02-14
1y Target Est120.07
Trade prices are not sourced from all markets
  • GuruFocus.com21 hours ago

    Eli Lilly and Co (LLY) Files 10-K for the Fiscal Year Ended on December 31, 2018

    Eli Lilly and Co is a pharmaceutical company with a focus on neuroscience, endocrinology, oncology, and immunology. The dividend yield of Eli Lilly and Co stocks is 1.91%. Warning! GuruFocus has detected 7 Warning Signs with LLY.

  • What Are Teva Pharmaceutical’s Key Growth Drivers in 2019?
    Market Realist22 hours ago

    What Are Teva Pharmaceutical’s Key Growth Drivers in 2019?

    Is Teva Pharmaceutical an Attractive Pick This February?(Continued from Prior Part)Growth driversOn its fourth-quarter earnings conference call, Teva Pharmaceutical (TEVA) highlighted Ajovy and Austedo as its key growth drivers for 2019.Copaxone

  • Bayer Obtains Full Rights to Vitrakvi From Lilly's Loxo
    Zacks23 hours ago

    Bayer Obtains Full Rights to Vitrakvi From Lilly's Loxo

    Bayer (BAYRY) obtains full exclusive licensing rights for the global development and commercialization of Vitrakvi (larotrectinib) and BAY 2731954 (LOXO-195) from Loxo.

  • Merck's (MRK) Stock Up Almost 50% in a Year: Here's Why
    Zacks23 hours ago

    Merck's (MRK) Stock Up Almost 50% in a Year: Here's Why

    Merck's (MRK) stock is up 45.2% in the past year. Here are reasons for the same.

  • Reutersyesterday

    Pfizer-Lilly drug shown to help reduce back pain in late-stage trial

    A non-opioid painkiller developed by Pfizer Inc and Eli Lilly and Co succeeded in reducing chronic low back pain when used in a stronger dose, results from a late-stage study showed on Tuesday. The drug was being tested in patients who had already used three different classes of painkillers but had not experienced enough relief or were intolerant to those treatments. Tanezumab belongs to a category of pain medications that target the nerve growth factor, a protein involved in the growth of nerve cells.

  • Reutersyesterday

    Higher dose of Pfizer-Lilly drug helps reduce back pain in study

    Pfizer and Eli Lilly said on Tuesday that a higher dose of their non-opioid drug tanezumab succeeded in reducing chronic low back pain in patients in a late-stage clinical study. However, a lower dose ...

  • Pfizer and Lilly Announce Top-line Results From Phase 3 Study of Tanezumab in Chronic Low Back Pain
    PR Newswireyesterday

    Pfizer and Lilly Announce Top-line Results From Phase 3 Study of Tanezumab in Chronic Low Back Pain

    NEW YORK and INDIANAPOLIS, Feb. 19, 2019 /PRNewswire/ -- Pfizer Inc. (PFE) and Eli Lilly and Company (LLY) today announced positive top-line results from a Phase 3 study evaluating tanezumab in patients with moderate-to-severe chronic low back pain (CLBP). In this study, CLBP was defined as low back pain that had persisted for more than three consecutive months. On average, they had CLBP for 10 years, and they reported a significant impact of their pain on their ability to function in everyday life.

  • Moody's5 days ago

    Elanco Animal Health Incorporated -- Moody's announces completion of a periodic review of ratings of Elanco Animal Health Incorporated

    Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Elanco Animal Health Incorporated and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers. This publication does not announce a credit rating action and is not an indication of whether or not a credit rating action is likely in the near future.

  • Primecap Management Trims Eli Lilly Position
    GuruFocus.com5 days ago

    Primecap Management Trims Eli Lilly Position

    Investment firm PRIMECAP Management (Trades, Portfolio) sold shares of the following stocks during the fourth quarter. Warning! GuruFocus has detected 7 Warning Signs with LLY. The pharmaceutical company has a market cap of $126.58 billion and an enterprise value of $131.29 billion.

  • Business Wire5 days ago

    Hagens Berman: Judge Denies Insulin Makers’ Motion to Dismiss Class-Action Lawsuit Regarding Skyrocketing Insulin Prices

    Today, a federal judge’s opinion has greenlighted a national class-action lawsuit filed against Sanofi, Novo Nordisk and Eli Lilly for their systematic overpricing of insulin and concealment of a behind-the-scenes arrangement orchestrated to hike insulin prices, according to attorneys at Hagens Berman. Brian R. Martinotti, U.S. District Judge for the District of New Jersey, granted in part and denied in part the drug companies’ motion to dismiss the case. The opinion allows state law claims from plaintiffs – people living with diabetes who Eli Lilly, Sanofi and Novo Nordisk have forced to pay skyrocketing insulin prices – and gave attorneys representing them ability to address concerns regarding individual state representation.

  • Reuters5 days ago

    Bayer gains full Vitrakvi rights from Eli Lilly's Loxo

    German drugmaker Bayer took full control of Vitrakvi, a drug used against a variety of cancers driven by a rare genetic mutation, in a deal with from Eli Lilly's Loxo Oncology. Bayer said on Friday it exercised a right to gain exclusive licensing rights for the global development and commercialization of Vitrakvi, also known as larotrectinib, under a clause in the initial collaboration deal with Loxo Oncology that provided for Loxo becoming a takeover target.

  • Alkermes (ALKS) Q4 Earnings & Revenues Surpass Estimates
    Zacks5 days ago

    Alkermes (ALKS) Q4 Earnings & Revenues Surpass Estimates

    Alkermes' (ALKS) earnings and sales exceed estimates in the fourth quarter of 2018.

  • Lilly Completes Acquisition of Loxo Oncology
    PR Newswire5 days ago

    Lilly Completes Acquisition of Loxo Oncology

    INDIANAPOLIS, Feb. 15, 2019 /PRNewswire/ -- Eli Lilly and Company (LLY) today announced the successful completion of its acquisition of Loxo Oncology, Inc. (LOXO). The acquisition broadens the scope of Lilly's oncology portfolio into precision medicines through the addition of a pipeline of highly selective potential medicines for patients with genomically defined cancers. Lilly's tender offer for all outstanding shares of common stock of Loxo Oncology, at a price of $235.00 per share in cash, expired as scheduled at one minute past 11:59 p.m., Eastern time, on Thursday, February 14, 2019.

  • Are You Looking for a High-Growth Dividend Stock? Eli Lilly (LLY) Could Be a Great Choice
    Zacks5 days ago

    Are You Looking for a High-Growth Dividend Stock? Eli Lilly (LLY) Could Be a Great Choice

    Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.

  • Lilly To Participate in Leerink Partners Global Healthcare Conference
    PR Newswire6 days ago

    Lilly To Participate in Leerink Partners Global Healthcare Conference

    INDIANAPOLIS , Feb. 14, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Leerink Partners Global Healthcare Conference on Wednesday, February 27, 2019 . Christi Shaw , president ...

  • Incyte (INCY) Q4 Earnings Miss Estimates, Revenues Beat
    Zacks6 days ago

    Incyte (INCY) Q4 Earnings Miss Estimates, Revenues Beat

    Incyte's (INCY) fourth-quarter earnings miss estimates but revenues beat the same on strong Jakafi sales.

  • 5 Drug/Biotech Stocks Set to Beat Estimates in Q4 Earnings
    Zacks6 days ago

    5 Drug/Biotech Stocks Set to Beat Estimates in Q4 Earnings

    Let us take a look at five favorable stocks, poised to beat estimates this earnings season.

  • InvestorPlace6 days ago

    Thursday’s Vital Data: Eli Lilly, Twitter and Freeport-McMoRan

    U.S. stock futures are trading higher again this morning, continuing this relief rally. In premarket action, the futures on the Dow Jones Industrial Average are up 0.46% and S&P 500 are higher by 0.39%. Nasdaq-100 have added 0.52% to yesterday's gains.In the options pits, call buyers were busier than bears yesterday. Markets meandered higher while waiting for some geo-economic news. We still need President Donald Trump to actually sign the agreement to avert a U.S. government shutdown. This rally could disappear quickly if news on that front disappoints. Meanwhile, Wall Street still has one foot out the door. Investors will sell first and ask questions later. Regardless, the action was bullish since we had 18.9 million calls and 15.2 million puts during the session.Markets seem on edge, even when in the green. This is the byproduct of being in headline trading mode while we await news from the tariff talks between the U.S. and China. Nevertheless, the CBOE single-session equity put/call volume ratio remain stable 0.57 versus the the 10-day moving average of 0.62. Sentiment remains positive in spite of the caution.InvestorPlace - Stock Market News, Stock Advice & Trading TipsOptions activity was bullish on Wednesday. This is normal as fear levels abate. Twitter (NYSE:TWTR) was in the news and spiked 4% and the action was also bullish in the options. Freeport-McMoRan (NYSE:FCX) had an even bigger rally, up almost 7% yesterday. The appetite for options was voracious, suggesting more potential to come. Finally, Eli Lilly (NYSE:LLY) wasn't as exciting on the Wednesday scoreboard, but its options action made up for it.Let's take a closer look: Eli Lilly (LLY)Eli Lilly stock might be ready to make a big move. This week the options have been active and the calls have overwhelmed the puts. Yesterday LLY options traded 727 times its daily average volume. While the split favors the bears slightly, it's even enough to leave the bias neutral. * 9 U.S. Stocks That Are Coming to Life Again Usually when options get to be this active, it means that there is an imminent move in the stock. This much action in it above the normal levels is unusual. Such a tense situation will resolve itself soon, but unfortunately we don't know the direction of the breakout.So we rely on the charts and the levels to tell us when to go long or short. Eli Lilly stock is at all time highs so clearly it's having a great year. Shorter term, it is stuck between $120.30 and $118.10 per share. A breach of either side of this range will carry momentum in that direction. The secondary targets from those edges are $121.40 versus $117.05. Those, too, are potential catalyst levels. It is best to trade the triggers rather than anticipate the moves. Twitter (TWTR)Twitter reported earnings recently, and the stock collapsed more than 10% on the headline. This was a shame, since TWTR stock was in the middle of a breakout from $34 per share. Luckily for bulls, on Wednesday it spiked sharply on the 13-F news that Morgan Stanley (NYSE:MS) has a new 5.6% stake in the stock. Investors chased the stock up but closed off the highs.So it is no surprise to see Twitter stock options trade 138 times their daily average. Moreover, 70% of the Wednesday options were calls to only 30% puts. It is clear that traders now expect a rebound from the earnings rout.Before chasing, it is important that it maintains the short-term higher-lows trend. So losing $30.30 would cause a deflation in the immediate rally. Conversely, a breach above $31.82 would trigger a buy signal to fill the earnings gap and target $34 per share. It would be a tall order to expect much more of it here. Freeport McMoRan (FCX)FCX reported earnings in January and the stock fell more than 15% on its heels. Since then, it completely recovered from it. But there might be even more good news and the options markets know it.On Wednesday, FCX options traded 204 times their daily average. More to the point, the mix was 76% calls to only 24% puts and this suggests a very bullish bias. The technicals point to much more upside off the breach of $12.10 per share.If the bulls can continue past $12.30 it could continue on its way to $13 or higher. There are resistance areas in between but this breakout has momentum. The concern from here that this stock moves fast but in both directions. And this fast recovery from earnings left a big gap below that beacons.Tight stops are a must when trading FCX stock. Those who are in it for an investment should trade it according to their fundamental opinions of it. I recently wrote a bullish article about the upside potential in FCX.Nicolas Chahine is the managing director of SellSpreads.com. As of this writing, he did not hold a position in any of the aforementioned securities. You can follow him as @racernic on Twitter and Stocktwits. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 9 U.S. Stocks That Are Coming to Life Again * The 7 Best Video Game Stocks to Power Up Your Portfolio! * 5 Tips to Become a Better Stock Trader Compare Brokers The post Thursdaya€™s Vital Data: Eli Lilly, Twitter and Freeport-McMoRan appeared first on InvestorPlace.

  • Teva (TEVA) Q4 Earnings Miss,'19 View Weak, Shares Down
    Zacks6 days ago

    Teva (TEVA) Q4 Earnings Miss,'19 View Weak, Shares Down

    Teva's (TEVA) fourth-quarter earnings miss estimates while sales marginally beat expectations. Guidance for 2019 is lower than expected.

  • Boehringer Ingelheim and Lilly announce the CAROLINA® cardiovascular outcome trial of Tradjenta® met its primary endpoint of non-inferiority compared with glimepiride
    PR Newswire6 days ago

    Boehringer Ingelheim and Lilly announce the CAROLINA® cardiovascular outcome trial of Tradjenta® met its primary endpoint of non-inferiority compared with glimepiride

    RIDGEFIELD, Conn. and INDIANAPOLIS, Feb. 14, 2019 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (LLY) announced CAROLINA® (CARdiovascular Outcome study of LINAgliptin versus glimepiride in patients with type 2 diabetes) met its primary endpoint, defined as non-inferiority for Tradjenta® (linagliptin) versus glimepiride in time to first occurrence of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke (3P-MACE). CAROLINA is the only active-comparator cardiovascular outcome trial for a dipeptidyl peptidase-4 (DPP-4) inhibitor.

  • Key Takeaways from Eli Lilly's (LLY) Q4 Earnings Report
    Zacks7 days ago

    Key Takeaways from Eli Lilly's (LLY) Q4 Earnings Report

    Here are the key takeaways from Eli Lilly's (LLY) fourth-quarter earnings conference call.

  • Moat Index: Dramatic Sector Allocation Shift in 2018
    Market Realist7 days ago

    Moat Index: Dramatic Sector Allocation Shift in 2018

    What Did 2018 Bring for Moat Stocks?(Continued from Prior Part)VanEck New Year, New Positioning The U.S. Moat Index is reviewed quarterly to ensure the Index is allocated to companies that Morningstar believes possess a sustainable competitive

  • Pfizer or Eli Lilly: Who Is Controlling Expenses Better?
    Market Realist7 days ago

    Pfizer or Eli Lilly: Who Is Controlling Expenses Better?

    How Pfizer and Eli Lilly Stack Up in February(Continued from Prior Part)Expense guidance for fiscal 2019 In its fourth-quarter earnings investor presentation, Pfizer (PFE) guided for adjusted cost of sales as a percentage of revenues of 20.8% to

  • What Are the Key Growth Drivers for Eli Lilly in Fiscal 2019?
    Market Realist7 days ago

    What Are the Key Growth Drivers for Eli Lilly in Fiscal 2019?

    How Pfizer and Eli Lilly Stack Up in February(Continued from Prior Part)Growth drivers In its fourth-quarter earnings investor presentation, Eli Lilly (LLY) highlighted its newer products such as Emgality, Verzenio, Olumiant, Lartruvo, Taltz,